HBIO Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Harvard Bioscience Inc (HBIO) is not a strong buy for a beginner, long-term investor at this time. The lack of positive trading signals, weak financial performance, and absence of significant catalysts suggest that waiting for clearer opportunities or stronger fundamentals would be prudent.
The technical indicators are mixed to bearish. The MACD is slightly positive but contracting, RSI is neutral at 43.848, and the moving averages indicate a bearish trend (SMA_200 > SMA_20 > SMA_5). The stock is trading near its pivot level of 5.101, with key resistance at 5.598 and support at 4.605. Overall, there is no strong technical signal for a buy.
The gross margin increased by 8.07% YoY to 56.13%, indicating some operational efficiency improvement. Analyst Bruce Jackson recently raised the price target to $6, which is above the current price.
Revenue dropped by 3.34% YoY in Q4 2025, and net income fell drastically by -15916.67% YoY, indicating significant financial struggles. The stock has a 30% chance of declining in the next day, week, and month based on historical patterns. No recent news, congress trading data, or significant insider/hedge fund activity suggests a lack of momentum or interest in the stock.
In Q4 2025, revenue dropped to $23.735M (-3.34% YoY), and net income plummeted to -$2.847M (-15916.67% YoY). EPS remained negative at -0.64, showing no improvement YoY. Gross margin improved to 56.13% (+8.07% YoY), but overall financial performance remains weak.
Analysts maintain a Speculative Buy rating, but the price target history has been volatile. The recent increase to $6 reflects some optimism, but the prior reduction to $0.60 highlights uncertainty in the company's recovery timeline.
